If You Invested in ECHOIQ LTD (ECHQF)

ECHOIQ LTD (trading as Echo IQ Limited on the ASX under the symbol EIQ) is described as an AI and medical technology company focused on cardiology. According to company disclosures, Echo IQ uses AI-driven technology and proprietary software to improve decision making in cardiology, with a particular emphasis on conditions such as heart failure and severe aortic stenosis (AS). The company is based in Sydney, Australia.

Echo IQ develops and validates clinical decision support software designed to work with echocardiogram data. Its EchoSolv-branded tools are presented as AI-powered systems that assist clinicians in identifying patients with specific cardiac conditions. The company reports that these tools are intended to support cardiologists and other healthcare professionals by analysing echocardiographic information and highlighting patients who may have heart failure or severe aortic stenosis.

EchoSolv HF – Heart Failure Decision Support

Echo IQ has disclosed the development of EchoSolv HF, a heart failure clinical decision support software. In collaboration with the Mayo Clinic Platform’s Validate program, EchoSolv HF underwent a clinical validation study using an independent dataset of approximately 17,000 individual echocardiogram studies from the Mayo Clinic Platform. The company states that this validation met its primary endpoint in detecting heart failure and that the results exceeded internal expectations.

According to Echo IQ, the validation highlighted performance metrics for EchoSolv HF in identifying patients with heart failure and in recognising patients who did not have heart failure. Completion of this clinical validation is described by the company as the final clinical requirement prior to a formal submission for clearance by the US Food & Drug Administration (FDA) via the 510(k) regulatory pathway. Echo IQ has indicated that it is in the process of completing this submission, with the goal of allowing EchoSolv HF to be marketed to and used by healthcare professionals in the United States as a clinical decision support software to aid in the detection of heart failure.

EchoSolv AS – Severe Aortic Stenosis Support

Echo IQ also highlights EchoSolv AS, which it describes as an AI-powered clinical decision support system focused on severe aortic stenosis. The company has reported results from studies presented at the American Heart Association Scientific Sessions, including an investigator-initiated study comparing traditional cardiologist reporting with EchoSolv in identifying severe AS phenotypes. Echo IQ states that, in this study, EchoSolv outperformed cardiologists in identifying severe AS phenotypes, particularly in women and low-gradient cases, and that EchoSolv-driven reporting restored gender equity in diagnosis in the study population.

Echo IQ further refers to a large real-world analysis of echocardiograms from the National Echo Database of Australia (NEDA), which examined haemodynamic profiles of aortic stenosis and associated health service delivery. The company notes that these findings suggest gaps between disease severity and treatment rates, and it positions EchoSolv AS as a tool that may enable more precise and consistent identification of high-risk AS patients, thereby supporting clinicians in making informed decisions about intervention.

Clinical and Research Collaborations

The company’s disclosures reference collaborations and studies involving organisations such as the Mayo Clinic Platform and the University of Notre Dame Australia, as well as data drawn from centres contributing to the National Echo Database of Australia. Echo IQ presents these collaborations and studies as part of the evidence base for its EchoSolv products, including independent evaluations of accuracy, efficacy and potential impact on clinical management.

Echo IQ also participates in healthcare industry events and conferences, such as the Piper Sandler Annual Healthcare Conference and the American Heart Association Scientific Sessions, where it highlights study results and the potential clinical applications of its AI-based decision support tools.

Business Focus

Based on available information, Echo IQ’s business focus centres on:

• Developing AI-driven, proprietary software for cardiology decision support.
• Targeting clinical use cases in heart failure and severe aortic stenosis through its EchoSolv HF and EchoSolv AS tools.
• Conducting and supporting validation studies and investigator-initiated research to assess performance and clinical utility.
• Pursuing regulatory pathways, including FDA 510(k) clearance for EchoSolv HF, to enable use of its software by healthcare professionals.

Echo IQ positions its technology as addressing gaps in the diagnosis and monitoring of cardiac conditions such as heart failure and severe aortic stenosis, particularly where existing diagnostic approaches may miss cases or contribute to delays in intervention.

Geographic and Market Context

Echo IQ is based in Sydney, Australia, and its disclosures indicate activity in both Australian and US healthcare contexts. For heart failure, the company cites data on the prevalence and economic impact of the condition in the United States and refers to plans to leverage its footprint in the US market following potential regulatory clearance of EchoSolv HF. For severe aortic stenosis, the company references global underdiagnosis and the use of data from Australian centres contributing to national databases.

Position in the AI and Medical Technology Space

Within the broader AI and medical technology sector, Echo IQ presents itself as an AI and medical technology company focused on cardiology decision support. Its emphasis on AI-driven analysis of echocardiogram data and clinical decision support software differentiates it from more general medical device or software providers. The company’s communications highlight independent validation, investigator-initiated studies, and participation in established clinical research and evaluation programs as key elements of its approach.

Use Cases for Investors and Observers

For investors and market observers, Echo IQ represents an example of an AI-focused medical technology company concentrating on specific cardiovascular indications. Its progress in clinical validation, regulatory submissions, and presentation of study data at major conferences are central themes in its public communications. The company’s disclosures emphasise the potential role of AI decision support tools in addressing underdiagnosis and treatment gaps in heart failure and severe aortic stenosis.